Sarah Kim

Sarah Kim, Ph.D.

Assistant Professor

Department: Pharmaceutics
Business Phone: (407) 313-7044
Business Email: sarahkim@cop.ufl.edu

About Sarah Kim

Sarah Kim, Ph.D. is a practicing pharmacometrician with a background in Applied Mathematics and a tenure-track Assistant Professor in the Department of Pharmaceutics at the University of Florida College of Pharmacy. As an early-stage Principal Investigator (PI), she is leading several funded computational modeling projects to create and innovate quantitative solutions in healthcare. The shared goal of these projects is to develop clinical trial simulation (CTS) tools. These tools will help drug developers optimize clinical trial designs to detect therapeutic effects more efficiently, therefore reducing clinical trial times, expenses, and participant burden. Her research teams are currently focusing on development of the CTS tools for type 1 diabetes (T1D) prevention studies in partnership with JDRF and C-Path’s Type 1 Diabetes Consortium (JDRF 2-SRA-2020-903-A-N, PI: Kim), and for efficacy evaluation studies of potential therapies in Duchenne muscular dystrophy (DMD) in collaboration with ImagingDMD and C-Path’s Duchenne Regulatory Science Consortium (NIH 1R21TR004006, PI: Kim). Using Artificial Intelligence (AI), her research team is also currently developing an imaging analysis and informatics tool to improve understanding of T1D progression (UF Informatics Institute AI SEED Fund, PI: Kim). She has received recognition including the David Goldstein Award and Presidential Trainee Awards from the American Society for Clinical Pharmacology and Therapeutics. Since 2020, she has been serving as an AI initiative committee member at the University of Florida College of Pharmacy.

Accomplishments

Peer Review Award for Pharmacology & Toxicology
2018 · Publons
Presidential Trainee Award
2018 · American Society for Clinical Pharmacology and Therapeutics
David Goldstein Trainee Award
2017 · American Society for Clinical Pharmacology and Therapeutics
Presidential Trainee Award
2017 · American Society for Clinical Pharmacology and Therapeutics
Landahl Travel Grant
2015 · Society of Mathematical Biology
Scholarship
2012-2013 · Southern Scholarship Foundation
Pi Mu Epsilon Honor
2012 · National Pi Mu Epsilon Council
Poster Presentation Award
2009 · Korean Society for Mathematical Biology
Graduate Research Fellowship
2008-2010 · LG Corporation Yonam Foundation
Summa Cum Laude Graduation Honors
2008 · Hanyang University
Volunteer Corps Essay Contest Award
2007 · Hanyang University
Scholarship
2006-2007 · Beakwoon Scholarship Foundation
Full Tuition Scholarship
2004-2007 · Hanyang University

Research Profile

Dr. Kim’s current research focuses on:

(1) Developing disease progression model-based clinical trial simulation tools to optimize clinical trial enrichment and design of studies to investigate the efficacy of potential therapies. She is currently focusing on optimizing clinical trial designs for Duchenne muscular dystrophy and type 1 diabetes.

(2) Developing Artificial Intelligence/Machine Learning (AI/ML)-assisted imaging analysis and informatics tools that will accelerate the analysis of imaging data and provide insights into better understanding of disease progression. Ultimately, the AI/ML-based tools will help in the rational design of disease prevention and treatment strategies.

(3) Population pharmacokinetic/pharmacodynamic (PK/PD)-modeling and simulation informing experimental designs of anti-Mycobacterium tuberculosis agents to identify optimal regimens which markedly shorten the length of tuberculosis treatments and prevent the emergence of resistance.

Publications

2021
Building optimal 3-drug combination chemotherapy regimens to eradicate Mycobacterium tuberculosis in its slow growth acid phase.
Antimicrobial agents and chemotherapy. [DOI] 10.1128/AAC.00693-21. [PMID] 34339275.
2021
Dose-fractionation of moxifloxacin for the treatment of tuberculosis: impact of dosing interval and elimination half-life on microbial kill and resistance suppression.
Antimicrobial agents and chemotherapy. [DOI] 10.1128/AAC.02533-20. [PMID] 33468465.
2021
In Vitro Synergistic Interactions of Isavuconazole and Echinocandins against Candida auris
Antibiotics. 10(4) [DOI] 10.3390/antibiotics10040355.
2021
Physiologically Based Pharmacokinetics Modeling to Investigate Formulation Factors Influencing the Generic Substitution of Dabigatran Etexilate.
CPT: pharmacometrics & systems pharmacology. [DOI] 10.1002/psp4.12589. [PMID] 33449439.
2021
The Funnel: a Screening Technique for Identifying Optimal Two-Drug Combination Chemotherapy Regimens.
Antimicrobial agents and chemotherapy. 65(2) [DOI] 10.1128/AAC.02172-20. [PMID] 33199386.
2020
Assessing the impact of cystic fibrosis on the antipyretic response of ibuprofen in children: Physiologically-based modeling as a candle in the dark.
British journal of clinical pharmacology. 86(11):2247-2255 [DOI] 10.1111/bcp.14326. [PMID] 32335930.
2020
Building Optimal Three-Drug Combination Chemotherapy Regimens.
Antimicrobial agents and chemotherapy. 64(11) [DOI] 10.1128/AAC.01610-20. [PMID] 32900682.
2020
Developing New Drugs for Mycobacterium tuberculosis Therapy: What Information Do We Get from Preclinical Animal Models?
Antimicrobial agents and chemotherapy. 64(12) [DOI] 10.1128/AAC.01376-20. [PMID] 32958720.
2020
Examination of Metoprolol Pharmacokinetics and Pharmacodynamics Across CYP2D6 Genotype-Derived Activity Scores.
CPT: pharmacometrics & systems pharmacology. 9(12):678-685 [DOI] 10.1002/psp4.12563. [PMID] 33067866.
2020
Machine Learning in Drug Discovery and Development Part 1: A Primer.
CPT: pharmacometrics & systems pharmacology. 9(3):129-142 [DOI] 10.1002/psp4.12491. [PMID] 31905263.
2020
Open Data Revolution in Clinical Research: Opportunities and Challenges.
Clinical and translational science. 13(4):665-674 [DOI] 10.1111/cts.12756. [PMID] 32004409.
2020
Pharmacokinetics of tedizolid, sutezolid, and sutezolid-M1 in non-human primates.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 151 [DOI] 10.1016/j.ejps.2020.105421. [PMID] 32531349.
2020
Predicting Cost-Effectiveness of Generic vs. Brand Dabigatran Using Pharmacometric Estimates Among Patients with Atrial Fibrillation in the United States.
Clinical and translational science. 13(2):352-361 [DOI] 10.1111/cts.12719. [PMID] 32053288.
2020
Quantitative Benefit-Risk Assessment of P-gp-Mediated Drug-Drug Interactions of Dabigatran Coadministered With Pharmacokinetic Enhancers in Patients With Renal Impairment.
Clinical pharmacology and therapeutics. [DOI] 10.1002/cpt.2087. [PMID] 33073366.
2020
Using Physiologically Based Pharmacokinetic Modeling to Assess the Risks of Failing Bioequivalence Criteria: a Tale of Two Ibuprofen Products.
The AAPS journal. 22(5) [DOI] 10.1208/s12248-020-00495-4. [PMID] 32830289.
2019
Evaluating the Clinical Impact of Formulation Variability: A Metoprolol Extended-Release Case Study.
Journal of clinical pharmacology. 59(9):1266-1274 [DOI] 10.1002/jcph.1433. [PMID] 31087554.
2019
Pharmacometrics, Physiologically Based Pharmacokinetics, Quantitative Systems Pharmacology-What’s Next?-Joining Mechanistic and Epidemiological Approaches.
CPT: pharmacometrics & systems pharmacology. 8(6):352-355 [DOI] 10.1002/psp4.12425. [PMID] 31179639.
2019
Towards regulatory endorsement of drug development tools to promote the application of model-informed drug development in Duchenne muscular dystrophy.
Journal of pharmacokinetics and pharmacodynamics. 46(5):441-455 [DOI] 10.1007/s10928-019-09642-7. [PMID] 31127458.
2017
Alterations in Pharmacokinetics of Gemcitabine and Erlotinib by Concurrent Administration of Hyangsayukgunja-Tang, a Gastroprotective Herbal Medicine.
Molecules (Basel, Switzerland). 22(9) [DOI] 10.3390/molecules22091515. [PMID] 28891960.
2015
A Biomechanical Model of Cortical Folding
Association for Women in Mathematics Series. 41-55 [DOI] 10.1007/978-3-319-16348-2_4.

Grants

Sep 2021 ACTIVE
Optimizing Muscular Dystrophy Clinical Trial Designs using Modeling and Simulation
Role: Principal Investigator
Funding: NATL INST OF HLTH NCATS
Feb 2020 ACTIVE
A Model-based Clinical Trial Simulation Tool to Optimize Clinical Trial Designs for Type 1 Diabetes Prevention Studies
Role: Principal Investigator
Funding: JDRF
Jul 2019 ACTIVE
OoR Matching Support for CTSI
Role: Project Manager
Funding: UF DIV OF SPONSORED RES MATCHING FUNDS
Mar 2019 – Mar 2020
A Model-based Clinical Trial Simulation Tool to Optimize Clinical Trial Design of Studies to Investigate Efficacy of Potential Therapies for Duchenne Muscular Dystrophy
Role: Principal Investigator
Funding: CRITICAL PATH INSTITUTE

Education

Ph.D.
2015 · Florida State University
M.S.
2010 · Hanyang University
B.S.
2008 · Hanyang University

Teaching Profile

Courses Taught
2021
PHA6125 Introduction to Quantitative Pharmacology

Contact Details

Phones:
Business:
(407) 313-7044
Emails: